Biomarkers For Enhanced Vaccine Safety (BioVacSafe)
Forskningsprojekt , 2012 – 2017

On March 1st 2012 the IMI-JU funded project – Biomarkers for Enhanced Vaccine Safety (BioVacSafe) – initiated its collaborative work to develop new tools that will improve the evaluation and monitoring of vaccine immunosafety. BioVacSafe is a public private consortium of 19 partners involving three of Europe's leading vaccine producing companies, experts from major academic institutions, small and medium-sized enterprises (SMEs) and non-governmental organization (NGO) actors. The total budget of the project is 30.2 millions of Euros and it will last for five years. BioVacSafe aims at establishing tools, methods and guidelines for the evaluation of vaccine reactogenicity and enhancing immunosafety of novel vaccines. In that context, BioVacSafe partners have a unique opportunity to tackle the urgent need to establish new ways of collaboration among industry, academia, biotech companies, regulators and patients' organizations to promote and support R&D for safer vaccines

Deltagare

Jens B Nielsen (kontakt)

Professor vid Chalmers, Biologi och bioteknik

Samarbetspartners

CDISC European Foundation

Woluwe-Saint Lambert, Belgium

Charité Universitätsmedizin Berlin

Berlin, Germany

Department Of Health

Leeds, United Kingdom

GlaxoSmithKline Biologicals - Belgium

Rixensart, Belgium

Göteborgs universitet

Gothenburg, Sweden

ImmunArray

Rehovot, Israel

Imperial College London

London, United Kingdom

Le Commissariat à l’Énergie Atomique et aux Énergies Alternatives (CEA)

Gif-sur-Yvette, France

Max-Planck-Gesellschaft

München, Germany

Novartis Vaccines & Diagnostics

Siena, Italy

Sanofi Pasteur

Lyon, France

St George's Univerity of London

London, United Kingdom

Statens Serum Institut

Köpenhamn, Denmark

Università degli Studi di Siena

Siena, Italy

Universiteit Gent

Gent, Belgium

Universiteit Utrecht

Utrecht, Netherlands

University of Surrey

Surrey, United Kingdom

VisMederi

Siena, Italy

Finansiering

Europeiska kommissionen (FP7)

Finansierar Chalmers deltagande under 2012–2017

Mer information

Projektets webbplats

www.biovacsafe.eu

Senast uppdaterat

2019-11-15